1.Browning JD., Szczepaniak LS., Dobbins R., Nuremberg P., Horton JD., Cohen JC. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004. 40:1387–95.
Article
2.Vernon G., Baranova A., Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011. 34:274–85.
Article
3.Younossi ZM., Koenig AB., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, inci-dence, and outcomes. Hepatology. 2016. 64:73–84.
Article
4.Kim KS., Lee BW., Kim YJ., Lee DH., Cha BS., Park CY. Nonalcoholic fatty liver disease and diabetes: part II: treatment. Diabetes Metab J. 2019. 43:127–43.
Article
5.Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005. 100:1082–90.
Article
6.Loomba R., Lutchman G., Kleiner DE., Ricks M., Feld JJ., Borg BB. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2009. 29:172–82.
Article
7.Lavine JE., Schwimmer JB., Van Natta ML., Molleston JP., Murray KF., Rosenthal P. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011. 305:1659–68.
Article
8.Li Y., Liu L., Wang B., Wang J., Chen D. Metformin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2013. 1:57–64.
Article
9.Belfort R., Harrison SA., Brown K., Darland C., Finch J., Hardies J. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006. 355:2297–307.
Article
10.Sanyal AJ., Chalasani N., Kowdley KV., McCullough A., Die- hl AM., Bass NM. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010. 362:1675–85.
Article
11.Musso G., Cassader M., Paschetta E., Gambino R. Thi-azolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017. 177:633–40. Erratum in: JAMA Intern Med 2017; 177:747.
Article
12.Choung S., Joung KH., You BR., Park SK., Kim HJ., Ku BJ. Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice. PPAR Res. 2018. 2018:4292509.
Article
13.Lee YH., Kim JH., Kim SR., Jin HY., Rhee EJ., Cho YM. Lobeglitazone, a novel thiazolidinedione, improves nonalcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017. 32:60–9.
Article
14.Hur KY., Moon MK., Park JS., Kim SK., Lee SH., Yun JS. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021. 45:461–81.
Article
15.Armstrong MJ., Gaunt P., Aithal GP., Barton D., Hull D., Parker R. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016. 387:679–90.
Article
16.Kuchay MS., Krishan S., Mishra SK., Choudhary NS., Singh MK., Wasir JS. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020. 63:2434–45.
Article
17.Newsome PN., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V. A placebo-controlled trial of subcutane-ous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021. 384:1113–24.
Article
18.Hartman ML., Sanyal AJ., Loomba R., Wilson JM., Nikoo-ienejad A., Bray R. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020. 43:1352–5.
Article
19.Kato H., Nagai Y., Ohta A., Tenjin A., Nakamura Y., Tsuki-yama H. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. diabetes Res Clin Pract. 2015. 109:199–205.
Article
20.Cui J., Philo L., Nguyen P., Hofflich H., Hernandez C., Bet-tencourt R. Sitagliptin vs. placebo for nonalcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016. 65:369–76.
Article
21.Fukuhara T., Hyogo H., Ochi H., Fujino H., Kan H., Naeshi-ro N. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology. 2014. 61:323–8.
22.Macauley M., Hollingsworth KG., Smith FE., Thelwall PE., Al-Mrabeh A., Schweizer A. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015. 100:1578–85.
Article
23.Mashitani T., Noguchi R., Okura Y., Namisaki T., Mitoro A., Ishii H. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016. 4:183–7.
Article
24.Eriksson JW., Lundkvist P., Jansson PA., Johansson L., Kvar-nström M., Moris L. Effects of dapagliflozin and n-3 carboxylic acids on nonalcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018. 61:1923–34.
Article
25.Kuchay MS., Krishan S., Mishra SK., Farooqui KJ., Singh MK., Wasir JS. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). diabetes Care. 2018. 41:1801–8.
Article
26.Cusi K., Bril F., Barb D., Polidori D., Sha S., Ghosh A. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019. 21:812–21.
Article
27.Ito D., Shimizu S., Inoue K., Saito D., Yanagisawa M., Inukai K. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017. 40:1364–72.
Article
28.Han E., Lee YH., Lee BW., Kang ES., Cha BS. Ipragliflozin additively ameliorates nonalcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial. J Clin Med. 2020. 9:259.
Article